SUNNYVALE, Calif., Aug. 7 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today
announced that the United States Army Medical Research and Materiel Command
(USAMRMC) has expanded the scope and increased funding for its development
contract from $1.35M to $1.9M for the development of accelerated, fully
automated DNA analysis systems that process and detect pathogenic spores.
All systems will be designed to be portable and will incorporate sample
concentration, spore lysis, DNA amplification and detection. Sample
preparation will be integrated in a unique, disposable cartridge that will be
based upon Cepheid's technology platforms in microfluidics and micromachining.
Cepheid's patented I-CORE(R) technology will be integrated as the
amplification and detection platform for the units. The first prototype is
scheduled to be delivered to Army investigators before the end of the year
with final prototype deliveries planned to occur during the first half of
2001.
Cepheid is applying proprietary microfluidic and microelectronic
technologies to the development of fast, versatile, miniaturized systems that
can perform all the steps required to analyze complex biological
samples -- including sample preparation, amplification and detection -- with a
single platform. Cepheid is initially focused on the detection of DNA and RNA
in such application areas as life sciences research, clinical diagnostics,
industrial testing and pharmacogenomics.
All statements in this press release that are not historical are
forward-looking statements with the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results of Cepheid to differ materially, including uncertainties relating to
the early stage of Cepheid's research and uncertainties regarding actual
market opportunities for products from such research. Such other risks are
discussed in Cepheid's Registration Statement on Form S-1, as amended,
initially filed with the Securities and Exchange Commission ("SEC") on
April 7, 2000 and in Cepheid's periodic reports filed with SEC. Cepheid
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Cepheid's expectation and with regard thereto or any
change in events, conditions or circumstances on which any such statements are
based.
NOTE: I-CORE is an U.S. trademark used by Cepheid.
SOURCE Cepheid
 back to top
Related links:
http://www.cepheid.com
CONTACT:
Cathy Smith, CFO of Cepheid, 408-541-4191,
ext. 230
|
